{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:09:37Z","timestamp":1749701377612,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,11]]},"DOI":"10.7759\/cureus.85755","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:40:26Z","timestamp":1749638426000},"source":"Crossref","is-referenced-by-count":0,"title":["Bisphosphonate Use in Acute Spinal Cord Injury: A Focused Systematic Review on Zoledronic Acid"],"prefix":"10.7759","author":[{"given":"Sojeong","family":"Mun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roopa","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Van de Vel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranav S","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab Ud Din","family":"Zia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03514-9","article-title":"Global incidence and characteristics of spinal cord injury since 2000-2021: a systematic review and meta-analysis","volume":"22","author":"Lu Y","year":"2024","unstructured":"Lu Y, Shang Z, Zhang W, et al.. Global incidence and characteristics of spinal cord injury since 2000-2021: a systematic review and meta-analysis. BMC Med. 2024, 22:285. 10.1186\/s12916-024-03514-9","journal-title":"BMC Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1310\/sci1901-1","article-title":"Causes of spinal cord injury","volume":"19","author":"Chen Y","year":"2013","unstructured":"Chen Y, Tang Y, Vogel LC, Devivo MJ. Causes of spinal cord injury. Top Spinal Cord Inj Rehabil. 2013, 19:1-8. 10.1310\/sci1901-1","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2015.02.027","article-title":"Prospective study of the occurrence of psychological disorders and comorbidities after spinal cord injury","volume":"96","author":"Craig A","year":"2015","unstructured":"Craig A, Nicholson Perry K, Guest R, et al.. Prospective study of the occurrence of psychological disorders and comorbidities after spinal cord injury. Arch Phys Med Rehabil. 2015, 96:1426-34. 10.1016\/j.apmr.2015.02.027","journal-title":"Arch Phys Med Rehabil"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2010.10.036","article-title":"A longitudinal study of depression from 1 to 5 years after spinal cord injury","volume":"92","author":"Hoffman JM","year":"2011","unstructured":"Hoffman JM, Bombardier CH, Graves DE, Kalpakjian CZ, Krause JS. A longitudinal study of depression from 1 to 5 years after spinal cord injury. Arch Phys Med Rehabil. 2011, 92:411-8. 10.1016\/j.apmr.2010.10.036","journal-title":"Arch Phys Med Rehabil"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/21925682211031190","article-title":"Direct cost of illness for spinal cord injury: a systematic review","volume":"12","author":"Malekzadeh H","year":"2022","unstructured":"Malekzadeh H, Golpayegani M, Ghodsi Z, et al.. Direct cost of illness for spinal cord injury: a systematic review. Global Spine J. 2022, 12:1267-81. 10.1177\/21925682211031190","journal-title":"Global Spine J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2022.11.069","article-title":"Bisphosphonates alleviate bone loss in people with acute spinal cord injury: a systematic review and meta-analysis","volume":"170","author":"Ma Z","year":"2023","unstructured":"Ma Z, Ma M, He Y, Sun H, Yang B, Dong H, Wang Y. Bisphosphonates alleviate bone loss in people with acute spinal cord injury: a systematic review and meta-analysis. World Neurosurg. 2023, 170:e584-95. 10.1016\/j.wneu.2022.11.069","journal-title":"World Neurosurg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2017.1329076","article-title":"Assessment and management of acute spinal cord injury: from point of injury to rehabilitation","volume":"40","author":"Hachem LD","year":"2017","unstructured":"Hachem LD, Ahuja CS, Fehlings MG. Assessment and management of acute spinal cord injury: from point of injury to rehabilitation. J Spinal Cord Med. 2017, 40:665-75. 10.1080\/10790268.2017.1329076","journal-title":"J Spinal Cord Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.31616\/asj.2019.0004","article-title":"Evaluating bone loss with bone turnover markers following acute spinal cord injury","volume":"14","author":"Thakkar P","year":"2020","unstructured":"Thakkar P, Prakash NB, Tharion G, Shetty S, Paul TV, Bondu J, Yadav B. Evaluating bone loss with bone turnover markers following acute spinal cord injury. Asian Spine J. 2020, 14:97-105. 10.31616\/asj.2019.0004","journal-title":"Asian Spine J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4416","article-title":"Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial","volume":"36","author":"Edwards WB","year":"2021","unstructured":"Edwards WB, Haider IT, Simonian N, Barroso J, Schnitzer TJ. Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial. J Bone Miner Res. 2021, 36:2127-38. 10.1002\/jbmr.4416","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092581","article-title":"Rehabilitation: neurogenic bone loss after spinal cord injury","volume":"11","author":"Leone GE","year":"2023","unstructured":"Leone GE, Shields DC, Haque A, Banik NL. Rehabilitation: neurogenic bone loss after spinal cord injury. Biomedicines. 2023, 11:10.3390\/biomedicines11092581","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200504115747","article-title":"The effect of bisphosphonates on managing osteoporosis after spinal cord injury: a meta-analysis","volume":"26","author":"Xinghua J","year":"2020","unstructured":"Xinghua J, Junjie W, Yao G, Peng S, Jianzhong H. The effect of bisphosphonates on managing osteoporosis after spinal cord injury: a meta-analysis. Curr Pharm Des. 2020, 26:5072-8. 10.2174\/1381612826666200504115747","journal-title":"Curr Pharm Des"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13060966","article-title":"The pathophysiology, identification and management of fracture risk, sublesional osteoporosis and fracture among adults with spinal cord injury","volume":"13","author":"Craven BC","year":"2023","unstructured":"Craven BC, Cirnigliaro CM, Carbone LD, Tsang P, Morse LR. The pathophysiology, identification and management of fracture risk, sublesional osteoporosis and fracture among adults with spinal cord injury. J Pers Med. 2023, 13:10.3390\/jpm13060966","journal-title":"J Pers Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2323-8","article-title":"Bone mineral loss at the proximal femur in acute spinal cord injury","volume":"24","author":"Edwards WB","year":"2013","unstructured":"Edwards WB, Schnitzer TJ, Troy KL. Bone mineral loss at the proximal femur in acute spinal cord injury. Osteoporos Int. 2013, 24:2461-9. 10.1007\/s00198-013-2323-8","journal-title":"Osteoporos Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05705-5","article-title":"Exploring changes in bone mass in individuals with a chronic spinal cord injury","volume":"32","author":"El-Kotob R","year":"2021","unstructured":"El-Kotob R, Craven BC, Thabane L, Papaioannou A, Adachi JD, Giangregorio LM. Exploring changes in bone mass in individuals with a chronic spinal cord injury. Osteoporos Int. 2021, 32:759-67. 10.1007\/s00198-020-05705-5","journal-title":"Osteoporos Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/00469580241278018","article-title":"Basal metabolic rate versus dietary vitamin D and calcium intakes and the association with body composition and bone health after chronic spinal cord injury","volume":"61","author":"Dora IE","year":"2024","unstructured":"Dora IE, Khalil RE, Adler RA, Gorgey AS. Basal metabolic rate versus dietary vitamin D and calcium intakes and the association with body composition and bone health after chronic spinal cord injury. Inquiry. 2024, 61:469580241278018. 10.1177\/00469580241278018","journal-title":"Inquiry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s43465-020-00158-8","article-title":"Zoledronic acid attenuates early bone loss at forearm in patients with acute spinal cord injury","volume":"54","author":"Goenka S","year":"2020","unstructured":"Goenka S, Sethi S. Zoledronic acid attenuates early bone loss at forearm in patients with acute spinal cord injury. Indian J Orthop. 2020, 54:127-33. 10.1007\/s43465-020-00158-8","journal-title":"Indian J Orthop"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05807-0","article-title":"The efficacy and safety of bisphosphonate analogs for treatment of osteoporosis after spinal cord injury: a systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Wu Y","year":"2021","unstructured":"Wu Y, Wang F, Zhang Z. The efficacy and safety of bisphosphonate analogs for treatment of osteoporosis after spinal cord injury: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2021, 32:1117-27. 10.1007\/s00198-020-05807-0","journal-title":"Osteoporos Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41393-020-0431-9","article-title":"The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study","volume":"58","author":"Oleson CV","year":"2020","unstructured":"Oleson CV, Marino RJ, Formal CS, Modlesky CM, Leiby BE. The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study. Spinal Cord. 2020, 58:921-9. 10.1038\/s41393-020-0431-9","journal-title":"Spinal Cord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41393-018-0195-7","article-title":"Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial","volume":"56","author":"Goenka S","year":"2018","unstructured":"Goenka S, Sethi S, Pandey N, Joshi M, Jindal R. Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial. Spinal Cord. 2018, 56:1207-11. 10.1038\/s41393-018-0195-7","journal-title":"Spinal Cord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2016.01.012","article-title":"Zoledronic acid treatment after acute spinal cord injury: results of a randomized, placebo-controlled pilot trial","volume":"8","author":"Schnitzer TJ","year":"2016","unstructured":"Schnitzer TJ, Kim K, Marks J, Yeasted R, Simonian N, Chen D. Zoledronic acid treatment after acute spinal cord injury: results of a randomized, placebo-controlled pilot trial. PM R. 2016, 8:833-43. 10.1016\/j.pmrj.2016.01.012","journal-title":"PM R"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9 Suppl 4","author":"Conte P","year":"2004","unstructured":"Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004, 9 Suppl 4:28-37. 10.1634\/theoncologist.9-90004-28","journal-title":"Oncologist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.10071","article-title":"Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption","volume":"55","author":"Green JR","year":"2002","unstructured":"Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res. 2002, 55:210-24. 10.1002\/ddr.10071","journal-title":"Drug Dev Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref27","unstructured":"Scientific image and illustration software | BioRender. (2025). Accessed. January 7, 2025: https:\/\/biorender.com\/."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S6285","article-title":"Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management","volume":"2","author":"Dalle Carbonare L","year":"2010","unstructured":"Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf. 2010, 2:121-37. 10.2147\/DHPS.S6285","journal-title":"Drug Healthc Patient Saf"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2017-001258","article-title":"Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates","volume":"26","author":"Fobelo Lozano MJ","year":"2019","unstructured":"Fobelo Lozano MJ, S\u00e1nchez-Fidalgo S. Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates. Eur J Hosp Pharm. 2019, 26:4-9. 10.1136\/ejhpharm-2017-001258","journal-title":"Eur J Hosp Pharm"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate-associated adverse events","volume":"8","author":"Papapetrou PD","year":"2009","unstructured":"Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009, 8:96-110. 10.14310\/horm.2002.1226","journal-title":"Hormones (Athens)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X09352920","article-title":"Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis","volume":"2","author":"Rizzoli R","year":"2010","unstructured":"Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis. 2010, 2:3-16. 10.1177\/1759720X09352920","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2019.1708268","article-title":"Controversies regarding mobilisation and rehabilitation following acute spinal cord injury","volume":"34","author":"Afshari FT","year":"2020","unstructured":"Afshari FT, Choi D, Russo A. Controversies regarding mobilisation and rehabilitation following acute spinal cord injury. Br J Neurosurg. 2020, 34:123-6. 10.1080\/02688697.2019.1708268","journal-title":"Br J Neurosurg"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel KA","year":"2009","unstructured":"Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009, 84:632-7; quiz 638. 10.1016\/S0025-6196(11)60752-0","journal-title":"Mayo Clin Proc"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall D","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996, 312:1254-9. 10.1136\/bmj.312.7041.1254","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.12.016","article-title":"Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and Z-score, and reference databases","volume":"104","author":"Dimai HP","year":"2017","unstructured":"Dimai HP. Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and Z-score, and reference databases. Bone. 2017, 104:39-43. 10.1016\/j.bone.2016.12.016","journal-title":"Bone"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2007.057505","article-title":"The role of DXA bone density scans in the diagnosis and treatment of osteoporosis","volume":"83","author":"Blake GM","year":"2007","unstructured":"Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007, 83:509-17. 10.1136\/pgmj.2007.057505","journal-title":"Postgrad Med J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.J.00160","article-title":"Hounsfield units for assessing bone mineral density and strength: a tool for osteoporosis management","volume":"93","author":"Schreiber JJ","year":"2011","unstructured":"Schreiber JJ, Anderson PA, Rosas HG, Buchholz AL, Au AG. Hounsfield units for assessing bone mineral density and strength: a tool for osteoporosis management. J Bone Joint Surg Am. 2011, 93:1057-63. 10.2106\/JBJS.J.00160","journal-title":"J Bone Joint Surg Am"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3171\/2014.5.FOCUS1483","article-title":"Use of computed tomography for assessing bone mineral density","volume":"37","author":"Schreiber JJ","year":"2014","unstructured":"Schreiber JJ, Anderson PA, Hsu WK. Use of computed tomography for assessing bone mineral density. Neurosurg Focus. 2014, 37:E4. 10.3171\/2014.5.FOCUS1483","journal-title":"Neurosurg Focus"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2004.09.006","article-title":"Fracture threshold in the femur and tibia of people with spinal cord injury as determined by peripheral quantitative computed tomography","volume":"86","author":"Eser P","year":"2005","unstructured":"Eser P, Frotzler A, Zehnder Y, Denoth J. Fracture threshold in the femur and tibia of people with spinal cord injury as determined by peripheral quantitative computed tomography. Arch Phys Med Rehabil. 2005, 86:498-504. 10.1016\/j.apmr.2004.09.006","journal-title":"Arch Phys Med Rehabil"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2557-5","article-title":"Bone mineral and stiffness loss at the distal femur and proximal tibia in acute spinal cord injury","volume":"25","author":"Edwards WB","year":"2014","unstructured":"Edwards WB, Schnitzer TJ, Troy KL. Bone mineral and stiffness loss at the distal femur and proximal tibia in acute spinal cord injury. Osteoporos Int. 2014, 25:1005-15. 10.1007\/s00198-013-2557-5","journal-title":"Osteoporos Int"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone turnover markers in the diagnosis and monitoring of metabolic bone disease","volume":"63","author":"Greenblatt MB","year":"2017","unstructured":"Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem. 2017, 63:464-74. 10.1373\/clinchem.2016.259085","journal-title":"Clin Chem"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas PD","year":"2009","unstructured":"Delmas PD, Munoz F, Black DM, et al.. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009, 24:1544-51. 10.1359\/jbmr.090310","journal-title":"J Bone Miner Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376931-bisphosphonate-use-in-acute-spinal-cord-injury-a-focused-systematic-review-on-zoledronic-acid","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:40:27Z","timestamp":1749638427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376931-bisphosphonate-use-in-acute-spinal-cord-injury-a-focused-systematic-review-on-zoledronic-acid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.85755","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}